Quarterly ResultMay 11, 2026, 04:14 PM
Acurx Pharmaceuticals Q1 Net Loss $(1.68)M; Going Concern Doubt
AI Summary
Acurx Pharmaceuticals reported a net loss of $(1.68) million for Q1 2026, an improvement from $(2.15) million in Q1 2025. The company's cash balance stood at $9.3 million as of March 31, 2026, which management believes is insufficient to meet anticipated cash requirements for the next 12 months, raising substantial doubt about its ability to continue as a going concern. The company continues to fund operations through equity financing, including $3.11 million from an equity line of credit in Q1 2026.
Key Highlights
- Q1 2026 net loss was $(1.68) million, an improvement from $(2.15) million in Q1 2025.
- Basic and diluted loss per share was $(0.62) in Q1 2026, compared to $(2.15) in Q1 2025.
- Cash balance stood at $9.3 million as of March 31, 2026.
- Net cash used in operating activities decreased to $(1.41) million in Q1 2026.
- Research and development expenses fell to $341,468 in Q1 2026.
- General and administrative expenses decreased to $1.37 million in Q1 2026.
- Raised $3.11 million in Q1 2026 through an equity line of credit.
- Management expressed substantial doubt about the company's ability to continue as a going concern.